drugset
drugset / Trial / NCT04551534

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers

NCT04551534 ↗

Phase 1 Completed 122 enrolled Denali Therapeutics Inc.
RandomizedSequentialDouble-blindTreatment

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study conducted in three parts.

Timeline

Start
2017-06-01
Primary completion
2018-08-08
Completion
2018-08-08

Outcome

Met primary endpoint

release “Healthy volunteer study of DNL201 meets all objectives in phase 1 clinical study” denalitherapeutics.com ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject DNL201 Small molecule — Oral

Indications

No indication recorded.